Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired th...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2022-04, Vol.145 (15), p.e811-e838
Main Authors: Beavers, Craig J, Rodgers, Jo E, Bagnola, Aaron J, Beckie, Theresa M, Campia, Umberto, Di Palo, Katherine E, Okwuosa, Tochi M, Przespolewski, Eugene R, Dent, Susan
Format: Article
Language:English
Subjects:
American Heart Association
Cardiology
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - epidemiology
Humans
Medical Oncology
Neoplasms - drug therapy
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired therapeutic effect. Clinicians in both cardiology and oncology should be cognizant of these potential drug-drug interactions that may reduce the efficacy or safety of either cardiovascular or cancer therapies. These risks can be mitigated through increased recognition of potential drug-drug interaction, use of alternative medications when possible, and careful monitoring. This scientific statement provides clinicians with an overview of pharmacodynamic and pharmacokinetic drug-drug interactions in patients with cancer exposed to common cardiovascular and cancer medications.
ISSN:0009-7322
1524-4539
DOI:10.1161/CIR.0000000000001056